COYA

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Coya Therapeutics, Inc. Common Stock

NASDAQ | COYA

6.24

USD

$0.00

(

0.00%

)

At Close (As of Dec 1, 2025)

$136.22M

Market Cap

-

P/E Ratio

-1.11

EPS

$8.29

52 Week High

$4.65

52 Week Low

HEALTHCARE

Sector

COYA Chart

Recent Chart
Price Action

COYA Technicals

Tags:

COYA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$8.3M
Total Revenue $3.6M
Cost Of Revenue $12M
Costof Goods And Services Sold $12M
Operating Income -$17M
Selling General And Administrative $8.9M
Research And Development $12M
Operating Expenses $8.9M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $27K
Income Before Tax -$16M
Income Tax Expense -$720K
Interest And Debt Expense -
Net Income From Continuing Operations -$15M
Comprehensive Income Net Of Tax -
Ebit -$17M
Ebitda -$17M
Net Income -$15M

Revenue & Profitability

Earnings Performance

COYA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $44M
Total Current Assets $44M
Cash And Cash Equivalents At Carrying Value $38M
Cash And Short Term Investments $38M
Inventory -
Current Net Receivables $731K
Total Non Current Assets $39K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $38B
Other Current Assets $5.2M
Other Non Current Assets -
Total Liabilities $4.8M
Total Current Liabilities $3.8M
Current Accounts Payable $1.6M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $945K
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $1.4M
Other Non Current Liabilities -
Total Shareholder Equity $40M
Treasury Stock -
Retained Earnings -$41M
Common Stock $1.7K
Common Stock Shares Outstanding $15M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$10M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $27K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$25K
Cashflow From Financing $16M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$15M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$8.3M
Total Revenue $3.6M
Cost Of Revenue $12M
Costof Goods And Services Sold $12M
Operating Income -$17M
Selling General And Administrative $8.9M
Research And Development $12M
Operating Expenses $8.9M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $27K
Income Before Tax -$16M
Income Tax Expense -$720K
Interest And Debt Expense -
Net Income From Continuing Operations -$15M
Comprehensive Income Net Of Tax -
Ebit -$17M
Ebitda -$17M
Net Income -$15M

COYA News

COYA Profile

Coya Therapeutics, Inc. Common Stock Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Coya Therapeutics, Inc. is a clinical-stage biotechnology firm based in Houston, Texas, focused on pioneering therapies that optimize regulatory T cell (Treg) functionality to combat autoimmune and neurodegenerative diseases. Leveraging its proprietary platform, Coya is advancing a robust pipeline targeting critical conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis. As it advances through clinical trials, the company is strategically positioned to significantly impact the landscape of immune-mediated therapies, addressing substantial unmet medical needs and offering potential breakthroughs for patients.

LPTX
+368.57%
$2.05
DRCT
+3.38%
$0.11
PAVS
-92.57%
$0.07
BYND
+36.48%
$1.34
VHAI
0.00%
$0.00
NVDA
+1.64%
$179.92
KALA
+37.66%
$1.33
QTTB
+74.42%
$3.82
HBI
-1.82%
$6.47
BITF
-5.74%
$3.28
ASST
-6.25%
$1.05
IPG
-1.95%
$24.57
FTEL
+41.17%
$1.20
PLUG
-4.47%
$1.92
AAL
-0.64%
$13.96
INTC
-1.35%
$40.01
AXDX
-61.36%
$0.03
BMNR
-12.62%
$28.94
IVP
+3.78%
$0.12
NIO
-5.81%
$5.18
TSLA
0.00%
$430.14
TLRY
-3.76%
$0.78
PFE
-1.82%
$25.27
BURU
-8.63%
$0.22
CHR
+4.81%
$0.04
ADAP
-15.14%
$0.05
F
-0.90%
$13.16
ONDS
-4.05%
$7.58
NFE
+7.37%
$1.31
CLSK
-6.75%
$14.08
SOFI
-2.32%
$29.03
BTBT
-5.46%
$2.25
MARA
-2.45%
$11.52
BMNU
-24.98%
$6.14
AAPL
+1.52%
$283.10
AHMA
+198.12%
$14.34
RIVN
+1.77%
$17.16
SNAP
-0.52%
$7.64
SOND
-23.45%
$0.12
MSTR
-3.25%
$171.42
AMZN
+0.28%
$233.88
INHD
-22.06%
$0.17
YGMZ
-1.79%
$0.10
RMBL
+60.50%
$3.21
GOOGL
-1.65%
$314.89
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
ACHR
-4.23%
$7.46
WBD
-0.54%
$23.87
CNEY
-9.96%
$1.31
CIFR
-3.24%
$19.69
BTG
-0.43%
$4.60
SRM
+53.27%
$10.30
RPGL
+5.72%
$0.42
T
-0.88%
$25.79
CAN
-6.15%
$0.94
EXK
-5.33%
$9.40
RIG
-1.36%
$4.35
DNN
-1.56%
$2.52
HOOD
-4.08%
$123.24
AMD
+1.02%
$219.76
GRAB
-3.30%
$5.27
BBD
-2.16%
$3.62
WULF
-1.35%
$15.30
RGTI
-8.29%
$23.45
BAC
-0.76%
$53.24
WLGS
-5.57%
$0.04
GOOG
-1.56%
$315.12
MTSR
-0.35%
$70.50
HBAN
+1.47%
$16.54
PLTR
-0.56%
$167.49
AG
+1.90%
$15.52
PLTD
+0.71%
$7.09
HPE
+0.32%
$21.94
CRWV
+5.38%
$77.06
APLD
+4.09%
$28.21
HL
+1.66%
$17.10
ITUB
-1.41%
$7.69
KVUE
-0.74%
$17.22
NFLX
+1.44%
$109.13
AFMD
-34.94%
$0.18
VALE
+0.63%
$12.69
PRPH
-7.51%
$0.19
CPNG
-5.36%
$26.65
MSFT
-1.07%
$486.74
SOUN
-4.39%
$11.52
AVGO
-4.18%
$386.08
RUBI
-13.53%
$0.13
AGNC
-0.28%
$10.46
IREN
+1.42%
$48.49
SMCI
-1.29%
$33.41
SMR
-9.60%
$18.08
CDE
-1.79%
$16.96
BTE
0.00%
$3.22
TE
+8.49%
$4.47
TSLG
+0.10%
$9.27
VZ
-0.90%
$40.74
AUR
-4.77%
$3.99
ALIT
+3.89%
$2.36
NCT
-26.87%
$0.56
LPTX
+368.57%
$2.05
DRCT
+3.38%
$0.11
PAVS
-92.57%
$0.07
BYND
+36.48%
$1.34
VHAI
0.00%
$0.00
NVDA
+1.64%
$179.92
KALA
+37.66%
$1.33
QTTB
+74.42%
$3.82
HBI
-1.82%
$6.47
BITF
-5.74%
$3.28
ASST
-6.25%
$1.05
IPG
-1.95%
$24.57
FTEL
+41.17%
$1.20
PLUG
-4.47%
$1.92
AAL
-0.64%
$13.96
INTC
-1.35%
$40.01
AXDX
-61.36%
$0.03
BMNR
-12.62%
$28.94
IVP
+3.78%
$0.12
NIO
-5.81%
$5.18
TSLA
0.00%
$430.14
TLRY
-3.76%
$0.78
PFE
-1.82%
$25.27
BURU
-8.63%
$0.22
CHR
+4.81%
$0.04
ADAP
-15.14%
$0.05
F
-0.90%
$13.16
ONDS
-4.05%
$7.58
NFE
+7.37%
$1.31
CLSK
-6.75%
$14.08
SOFI
-2.32%
$29.03
BTBT
-5.46%
$2.25
MARA
-2.45%
$11.52
BMNU
-24.98%
$6.14
AAPL
+1.52%
$283.10
AHMA
+198.12%
$14.34
RIVN
+1.77%
$17.16
SNAP
-0.52%
$7.64
SOND
-23.45%
$0.12
MSTR
-3.25%
$171.42
AMZN
+0.28%
$233.88
INHD
-22.06%
$0.17
YGMZ
-1.79%
$0.10
RMBL
+60.50%
$3.21
GOOGL
-1.65%
$314.89
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
ACHR
-4.23%
$7.46
WBD
-0.54%
$23.87
CNEY
-9.96%
$1.31
CIFR
-3.24%
$19.69
BTG
-0.43%
$4.60
SRM
+53.27%
$10.30
RPGL
+5.72%
$0.42
T
-0.88%
$25.79
CAN
-6.15%
$0.94
EXK
-5.33%
$9.40
RIG
-1.36%
$4.35
DNN
-1.56%
$2.52
HOOD
-4.08%
$123.24
AMD
+1.02%
$219.76
GRAB
-3.30%
$5.27
BBD
-2.16%
$3.62
WULF
-1.35%
$15.30
RGTI
-8.29%
$23.45
BAC
-0.76%
$53.24
WLGS
-5.57%
$0.04
GOOG
-1.56%
$315.12
MTSR
-0.35%
$70.50
HBAN
+1.47%
$16.54
PLTR
-0.56%
$167.49
AG
+1.90%
$15.52
PLTD
+0.71%
$7.09
HPE
+0.32%
$21.94
CRWV
+5.38%
$77.06
APLD
+4.09%
$28.21
HL
+1.66%
$17.10
ITUB
-1.41%
$7.69
KVUE
-0.74%
$17.22
NFLX
+1.44%
$109.13
AFMD
-34.94%
$0.18
VALE
+0.63%
$12.69
PRPH
-7.51%
$0.19
CPNG
-5.36%
$26.65
MSFT
-1.07%
$486.74
SOUN
-4.39%
$11.52
AVGO
-4.18%
$386.08
RUBI
-13.53%
$0.13
AGNC
-0.28%
$10.46
IREN
+1.42%
$48.49
SMCI
-1.29%
$33.41
SMR
-9.60%
$18.08
CDE
-1.79%
$16.96
BTE
0.00%
$3.22
TE
+8.49%
$4.47
TSLG
+0.10%
$9.27
VZ
-0.90%
$40.74
AUR
-4.77%
$3.99
ALIT
+3.89%
$2.36
NCT
-26.87%
$0.56
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.